跳到正文
原文
梅斯医学·临床资讯·· 16 天前精选AI 评分66

AASLD 2026三项慢乙肝研究:停药方案、纤维化评估与肝癌预测模型的最新证据

AASLD 2026 | 慢乙肝领域国际动态速览

AI 导读

AASLD 2026公布三项慢乙肝临床研究。STOP RCT(NCT0410217)纳入120例HBsAg<100 IU/mL的HBeAg阴性CHB患者,随机至停药组或持续NA组;mITT人群中第144周停药组HBsAg清除率30.4%,显著高于持续治疗组的7.7%(P=0.005),但ALT≥2×ULN发生率亦更高(36.2% vs 7.7%,P<0.001)。

推荐理由

汇集AASLD 2026三项乙肝研究结果,涉及停药决策、风险分层与HCC筛查三个核心临床问题。

正文

深度解析医学证据,DeepEvidence为你支撑决策

2026年11月5日-9日,全球肝病领域顶级学术盛会-The Liver Meeting 2026 (AASLD 2026)在美国•丹佛召开。本届大会汇聚来自世界各地的肝病临床专家与基础研究学者,围绕病毒性肝炎、代谢功能障碍相关脂肪性肝病、肝硬化及其并发症、肝癌、肝移植和肝病基础研究等领域,集中展示前沿研究成果与临床诊疗新进展。

为助力广大读者精准捕捉会议的学术精髓,及时洞悉领域前沿动态,肝胆相照平台特别甄选会议摘要中的热点研究内容,本篇专题报道将聚焦“慢性乙型肝炎”这一关键领域,为广大同仁提供最新研究进展,展望其在临床实践中的广阔应用前景。

一 摘要编号:4084

HBeAg阴性慢性乙型肝炎患者停用核苷(酸)类似物的随机对照研究

STOPPING NUCLEOSIDE ANALOUGUES IN HBEAG NEGATIVE CHRONIC HEPATITIS B WITH HBSAG < 100 IU/ML LEADS TO HIGH RATES OF HBSAG LOSS BUT RISK OF ALT FLARES: HALT NUC RANDOMISED CONTROL TRIAL

作者:Seng Gee Lim1 Wei Lyn yang2 Rajneesh Kumar3 Jessica Tan4 Yin Mei Lee1 Guan Huei Lee1 Yock Young Dan1 Daniel Huang5 How Cheng Low6 Gladys Tan6 Htet Htet Toe Wai Khine1 Amy Tay1 Tiffany Fortney7 Mark Anderson7 Gavin Cloherty8 Liang Shen9

1 National University Health System

2 Tan Tock Seng Hospital

3 Singapore General Hospital

4 Changi General Hosptial

5 National University Hospital, Singapore

6 National University Hospital

7 Abbott Laboratories

8 Abbott

9 Singapore Clinical Research Institut

背景

尽管已有大量研究与临床试验数据支撑,HBeAg 阴性慢性乙型肝炎(CHB)患者能否停用核苷(酸)类似物(NA)目前仍存争议,不同指南推荐意见尚未统一。一项荟萃分析与元回归分析提示,HBsAg<100 IU/mL 或可作为 NA 停药的最佳界值,但该阈值尚未在临床试验中得到验证。

Background:Despite multiple studies and clinical trials there is still controversy with regards to stopping nucleos(t)ide analogue (NA) therapy in HBeAg negative Chronic Hepatitis B(CHB) reflected in differences in guideline recommendations. A meta-analysis with metaregression identified the level of HBsAg, namely HBsAg < 100 IU/ml as an optimal threshold to stop NA therapy but this has not been tested in clinical trials.

方法

本研究为研究者发起的多中心随机对照试验,纳入新加坡 4 家三级医院中接受 NA 治疗≥12 个月、HBsAg<100 IU/mL 的 HBeAg 阴性 CHB 患者;受试者按 2:1 比例随机分配至停药组或 NA 持续治疗组,并依据 HBsAg<10 IU/mL、≥10 IU/mL 进行分层。主要终点为随机化后第 144 周的 HBsAg 清除率;重点监测的安全性终点包括丙氨酸氨基转移酶(ALT)升高≥2 倍、≥5 倍、≥10 倍正常值上限(ULN)。采用意向治疗分析,使用 SPSS 软件开展统计学分析。临床试验注册号:NCT0410217(依原文记录)。

Methods:  We conducted an investigator initiated randomised control trial of HBeAg negative CHB patients on NA > 12months with HBsAg < 100 IU/ml randomised to 2:1 stop NA or continue NA stratified by HBsAg < 10 or ≥10 IU/ml with the primary endpoint of HBsAg loss 144 weeks after randomisation in a multicentre randomised clinical trial of four tertiary hospitals in Singapore (clinicaltrials.gov NCT0410217). Safety of special interest were ALT flares ≥2x upper limit of normal (ULN), 5xULN and 10xULN. Analysis was by intention-to-treat and SPSS was used to analyse the results.

 结果

共计 120 例患者完成随机分组,其中停药组(HALT)81 例,持续治疗组 39 例。修正意向治疗(mITT)人群共 117 例(停药组 78 例、持续治疗组 39 例):1 例基线阶段退出研究,另有 2 例基线访视时已实现 HBsAg 转阴。第 144 周时,停药组 HBsAg 清除率为 24/78(30.4%),持续治疗组为 3/39(7.7%),P=0.005。在获得 HBsAg 清除的患者中,停药组 15/24(62.5%)、持续治疗组 2/3(66.6%)发生 HBsAg 血清学转换(P=0.052)。

在预设的 HBsAg<10 IU/mL 亚组中,停药组与持续治疗组第 144 周 HBsAg 清除率分别为 13/21(61.9%)和 3/12(25.0%,P=0.071);该亚组 ALT≥10×ULN 发生率两组相近(8.7% vs 8.2%)。NA 疗程>10 年、既往接受干扰素治疗与更高的 HBsAg 清除率显著相关(P<0.05)。停药组与持续治疗组 ALT≥2×ULN、≥5×ULN、≥10×ULN 的发生率依次为 36.2% vs 7.7%(P<0.001)、22.5% vs 2.6%(P=0.006)、15.0% vs 2.6%(P=0.058);总胆红素≥1.5×ULN 发生率为 6.2% vs 2.6%(P=0.662),HBeAg 血清学逆转发生率为 11.2% vs 2.6%(P=0.163)。

停药组 4.17% 的患者因重度 ALT 升高住院,持续治疗组无该类住院事件;持续治疗组有 1 例受试者在新冠疫情期间因药物耗尽自行停药。基线 HBV RNA 可预测 ALT 升高(AUROC=0.683,95% CI:0.516~0.851,P=0.032);以≥1.70254 为截断值预测重度 ALT 升高(ALT>10×ULN),敏感度 100%、特异度 51.1%、阳性预测值 15.4%、阴性预测值 100%。

Results:A total of 120 (HALT 81, continue 39) patients were randomized. The mITT population included 117 (HALT 78, continue 39) patients. One patient withdrew at baseline and two patients whose HBsAg were negative at baseline visit. The primary mITT endpoint of HBsAg loss at 144 weeks was achieved in 24/78 (30.4%) HALT and 3/39 (7.7%) continue (p = 0.005). HBsAg seroconversion was seen in 15/24 (62.5%) and 2/3 (66.6%) patients with HBsAg loss in HALT and continue arms respectively (p = 0.052). Apriori subgroup analysis of HBsAg < 10 IU/ml showed HBsAg loss at 144 weeks in 13/21 (61.9%) HALT versus 3/12 (25%) continue arm (p = 0.071). ALT ≥10xULN was seen in 8.7% versus 8.2% of HALT and continue for patients with HBsAg < 10 IU/ml. NA treatment > 10years and prior interferon was associated with higher rates of HBsAg loss (p < 0.05). ALT flares of ≥2x ULN, 5xULN and 10xULN were seen in 36.2% vs 7.7%, 22.5% vs 2.6% and 15% vs 2.6% of HALT and continue patients respectively (p < 0.001, p = 0.006, and p = 0.058 respectively). Bilirubin ≥1.5xULN occurred in 6.2% of HALT and 2.6% of continue arms (p = 0.662). HBeAg seroreversion occurred in 11.2% of HALT and 2.6% of continue patients (p = 0.163). Hospitalisations due to severe ALT flare occurred in 4.17% of HALT and none in continue patients. One patient in continue arm stopped NA as he ran out of study medication during COVID. HBV RNA at baseline was predictive of ALT flares (AUROC = 0.683, 95% CI 0.516 – 0.851, p = 0.032). At the cut-off value of ≥1.70254, the sensitivity, specificity, PPV and NPV of predicting severe ALT flare (ALT > 10xULN) are 100%, 51.1%, 15.4% and 100% respectively.

结论

对于 HBsAg<100 IU/mL 的HBeAg阴性慢性乙型肝炎患者,停用 NA可获得更高的HBsAg清除率,但同时伴随重度ALT升高、HBeAg 血清学逆转及住院等明确安全风险。

Conclusion:While stopping NA in HBeAg negative CHB patients with HBsAg < 100 IU/ml comes with high rates of HBsAg loss, they carry a significant risk of severe ALT flares, HBeAg seroreversion, and hospitalisation.

二 摘要编号:4065

基于HBV DNA的治疗阈值无法充分反映慢性乙肝不确定期患者的肝纤维化负担及长期结局

HBV DNA-BASED TREATMENT THRESHOLDS FAIL TO REFLECT FIBROSIS BURDEN AND LONG-TERM OUTCOMES IN INDETERMINATE-PHASE CHRONIC HEPATITIS B

作者:Seung Up Kim1 Hanah Lee2 Tae Hyung Kim3 Yeon Seok Seo3 Dae Won Jun4 Soo Young Park5 Hyun Woong Lee1 Sang Gyune Kim6

1 Yonsei University College of Medicine

2 Chung-Ang University Hospital

3 Korea University College of Medicine

4 Hanyang University College of Medicine

5 Kyungpook National University College of Medicine

6 Mayo Clinic Rochester

背景

慢性乙型肝炎(CHB)不确定期患者的管理仍存在难点。目前临床治疗决策主要依据血清HBV DNA阈值,但该指标未必能够充分反映潜在肝纤维化负荷及远期预后。本研究旨在评估基于HBV DNA进行治疗分层的局限性,同时探讨肝纤维化程度对此类患者肝脏相关结局的预测价值。

Background:Management of patients with indeterminate-phase chronic hepatitis B (CHB) remains challenging because current decisions are largely based on serum HBV DNA thresholds, which may not adequately reflect underlying liver fibrosis burden or long-term prognosis. We investigated the clinical limitations of HBV DNA-based treatment stratification and evaluated whether fibrosis burden better predicts liver-related outcomes in patients with indeterminatephase CHB.

方法

本研究纳入497例接受肝活检的CHB不确定期患者开展回顾性分析。基线评估组织学纤维化分期、炎症分级及肝脂肪变程度,并根据HBV DNA水平结合现行指南治疗阈值对患者进行分层。研究的长期终点包括肝细胞癌(HCC)、肝硬化进展、肝功能失代偿以及肝脏相关复合终点事件。

Methods:We retrospectively analyzed 497 patients with indeterminate-phase CHB who underwent liver biopsy. Histologic fibrosis stage, inflammation grade, and steatosis were assessed at baseline, and patients were categorized according to HBV DNA levels and treatment eligibility based on current guideline thresholds. Long-term outcomes included hepatocellular carcinoma (HCC), cirrhosis progression, hepatic decompensation, and composite liver-related events.

 结果

中位随访时长148.0个月,总随访人年数5740.7人年;随访期间共50 例发生HCC,68例出现肝硬化进展,26例发生肝功能失代偿,109例出现肝脏相关复合终点事件。

多变量Cox回归分析提示,纤维化分期是肝脏相关结局的独立预测因素(每升高 1 期,HR=1.41,95% CI:1.15~1.72,P=0.0009);而 HBV DNA 水平与肝脏相关结局无独立统计学相关性(HR=0.90,95% CI:0.82~1.00,P=0.051)。按HBV DNA分层的结果与组织学纤维化负荷之间存在明显的不一致性:HBV DNA处于低至中等水平(<7 log IU/mL)的患者中,72.1% 已存在显著纤维化(≥F2);而 HBV DNA 高水平(>7 log IU/mL)患者中,35.5% 仅为轻微纤维化(F0~1)。

在显著纤维化(≥F2)人群中,80.3% 的患者 HBV DNA 为低至中等水平;在 HBV DNA 落在常规治疗阈值区间(4~8 log IU/mL)的患者中,20% 组织学上并无治疗指征。无创纤维化标志物对显著纤维化具备较好的诊断效能,其中 FibroScan 诊断≥F2、≥F3 纤维化及肝硬化的准确度最优,AUROC 分别为 0.818、0.877、0.870,优于 FIB‑4 指数与 APRI 评分。

Results: During a median follow-up of 148.0 months (total 5,740.7 person-years), 50 patients developed HCC, 68 showed cirrhosis progression, 26 experienced hepatic decompensation, [KSG1] and 109 developed composite liver-related events. In multivariable Cox analysis, fibrosis stage independently predicted liver-related outcomes (hazard ratio [HR] per 1-stage increase, 1.41; 95% confidence interval [CI], 1.15–1.72; P = 0.0009), whereas HBV DNA level was not independently associated with outcomes (HR, 0.90; 95% CI, 0.82–1.00; P = 0.051). Substantial discordance was observed between HBV DNA category and histologic fibrosis burden. Among patients with low-to-moderate HBV DNA levels ( < 7 log IU/mL), 72.1% had significant fibrosis ( ≥F2), while 35.5% of patients with high HBV DNA levels ( > 7 log IU/mL) had minimal fibrosis (F0–1). Among patients with significant fibrosis ( ≥F2), 80.3% had low-to-moderate HBV DNA levels, while among patients with HBV DNA levels within conventional treatment thresholds (4-8 log IU/ mL), 20% showed no histologic indication for treatment. Noninvasive fibrosis markers showed good diagnostic performance for predicting significant fibrosis. Fibroscan demonstrated the highest accuracy for ≥F2 fibrosis (AUROC 0.818), ≥F3 fibrosis (AUROC 0.877), and cirrhosis (AUROC 0.870), outperforming FIB-4 and APRI.

结论

现行单纯依靠 HBV DNA 设定的治疗阈值,容易对相当一部分 CHB 不确定期患者造成分层误判,既可能导致高危患者治疗不足,也可能使低危患者接受不必要的抗病毒治疗。在风险分层体系中整合纤维化负荷及无创纤维化检测指标,相比仅依靠 HBV DNA,或可更好地指导个体化治疗决策。

Conclusion:Current HBV DNAbased thresholds may misclassify a substantial proportion of patients with indeterminate-phase CHB, leading to both undertreatment of high-risk patients and overtreatment of low-risk patients. Risk stratification incorporating fibrosis burden, supported by noninvasive fibrosis markers, may improve individualized treatment decisions beyond HBV DNA-based approaches alone.

三 摘要编号:4026

PAGE-B与改良PAGE-B评分在拉丁美洲多国乙肝队列中的肝癌预测表现

PERFORMANCE OF PAGEB AND MODIFIED PAGE-B SCORES FOR HEPATOCELLULAR CARCINOMA IN A MULTI-NATIONAL LATIN AMERICAN HEPATITIS B COHORT

作者:Erin Mann1 Enrique Carrera Estupiñan2 Javier Diaz Ferrer3 Jhon Prieto Ortiz4 Domingo Balderramo5 Marco Arrese6 Andre Boonstra7 Angelo Mattos8 Jose Debes1

1 University of Minnesota

2 Universidad San Francisco de Quito

3 Universidad de San Martin de Pores

4 CEHYD (Centro de Enfermedades Hepáticas y Digestivas) 

5 Instituto Universitario de Ciencias Biomédicas de Córdoba 

6 Pontificia Universidad Católica de Chile

7 Erasmus University Medical Center

8 Federal University of Health Sciences of Porto Alegre

背景

PAGE‑B 评分可用于预测慢性乙型肝炎病毒(HBV)感染者的肝细胞癌(HCC)发生风险,辅助制定 HCC 监测策略。但该评分在拉丁美洲人群中的效能尚缺乏充分证据,既往相关数据仅来源于巴西。本研究基于拉丁美洲多中心 HBV 队列,评估 PAGE‑B 及其改良版本 mPAGE‑B 的 HCC 预测效能。

Background:The PAGE-B score predicts hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B virus (HBV) infection and is used to guide surveillance decisions. Performance of PAGE-B in Latin American populations has not been well characterized, with the available data coming only from Brazil. We evaluated PAGE-B and modified PAGE-B (mPAGE-B) in a multi-national Latin American HBV cohort.

方法

研究纳入阿根廷、巴西、智利、哥伦比亚、厄瓜多尔、秘鲁多家中心的横断面及前瞻性 HBV 感染队列;分析对象为具备完整 PAGE‑B 评分变量(年龄、性别、血小板计数)的患者。所有受试者计算 PAGE‑B 评分;在可获得血清白蛋白结果的亚组中进一步计算纳入白蛋白指标的 mPAGE‑B 评分,并在同一人群内对比两项评分。分层分析在总队列以及有明确抗病毒治疗记录的亚组中分别开展。前瞻性队列随访记录入组首诊后 12 个月内新发 HCC 事件。在各评分预设低风险界值下计算阴性预测值(NPV)与阳性预测值(PPV),采用配对预测值检验进行组间比较。

Methods: We analyzed HBV patients from cross-pal and prospective cohorts at sites in Argentina, Brazil, Chile, Colombia, Ecuador, and Peru. The analytic cohort was restricted to patients with complete data for the PAGE-B components (age, gender, platelets). PAGE-B was calculated for all patients; mPAGE-B, which adds serum albumin, was calculated for the subset with albumin data and compared with PAGE-B in the same patients. Analyses were performed in the full cohort and in the subgroup of patients with documented HBV treatment. In the prospective cohort, incident HCC over 12 months from first visit was identified. Negative predictive value (NPV) and positive predictive value (PPV) were calculated for each score at its low-risk cutoff. NPV and PPV were compared between scores using a paired test for predictive values.

 结果

横断面队列共纳入 258 例受试者,平均年龄 57.5±13.8 岁,男性占 58.1%;其中 91 例(35.3%)合并 HCC。病例来源:阿根廷 14 例、巴西 92 例、智利 3 例、哥伦比亚 4 例、厄瓜多尔 48 例、秘鲁 97 例。在总队列中,PAGE‑B 的 NPV 为 73.3%,PPV 为 37.9%。具备白蛋白检测结果的 201 例受试者中,49 例(24.4%)确诊 HCC;mPAGE‑B 的预测效能较 PAGE‑B 仅有小幅提升,NPV 分别为 94.4%、93.2%(P=0.61),PPV 分别为 28.5%、29.3%(P=0.40),差异均无统计学意义。

已接受抗病毒治疗亚组共 103 例,PAGE‑B 的 NPV、PPV 依次为 88.5%、13.0%;该亚组中 93 例有白蛋白数据,其中 11 例(11.8%)发生 HCC,mPAGE‑B 对比 PAGE‑B,NPV 为 90.5% vs 87.5%(P=0.49),PPV 为 12.5% vs 11.6%(P=0.51),差异同样无统计学意义。前瞻性队列仅观察到 1 例新发 HCC,不足以充分评价两项评分的预后预测能力。

Results:The cross-pal cohort included 258 patients (mean age 57.5 years, SD 13.8; 58.1% male), of whom 91 (35.3%) had HCC. Patients were from Argentina (n = 14), Brazil (n = 92), Chile (n = 3), Colombia (n = 4), Ecuador (n = 48), and Peru (n = 97). In the full cohort, PAGE-B had an NPV of 73.3% and PPV of 37.9%. Among patients with available albumin (n = 201), of whom 49 had HCC (24.4%), mPAGE-B performed slightly better than PAGE-B (NPV 94.4% vs. 93.2%, p = 0.61; PPV 28.5% vs. 29.3%, p = 0.40), though differences were not statistically significant. In the treated subgroup (n = 103), PAGE-B had an NPV of 88.5% and PPV of 13.0%; among treated patients with albumin values (n = 93), of whom 11 had HCC (11.8%), mPAGE-B again outperformed PAGE-B (NPV 90.5% vs. 87.5%, p = 0.49; PPV 12.5% vs. 11.6%, p = 0.51), though differences were not statistically significant. Only one patient developed incident HCC in the prospective cohort, limiting evaluation of the scores' prognostic performance.

结论

本研究为拉丁美洲首个多中心验证研究,结果显示PAGE‑B与 mPAGE‑B均具备较高的HCC阴性预测值,mPAGE‑B效能仅轻微占优。该结果支持在拉丁美洲HBV感染者中使用PAGE‑B和 mPAGE‑B 辅助 HCC 风险分层与监测决策。

Conclusion: In this first multi-country Latin American evaluation, both PAGE-B and mPAGEB demonstrated high NPV for HCC, with mPAGE-B performing slightly better. These findings support the utility of PAGE-B and mPAGE-B in guiding HCC surveillance decisions in Latin American patients with HBV.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言

来源:梅斯医学·临床资讯 · news.medsci.cn